
Supplements and Featured Publications
- Improving Members’ Outcomes Across the Continuum of Diabetes: Assessing the Impact of New Measures
- Volume 13
- Issue 2 Suppl
Participating Faculty
The American Journal of
Managed Care
This supplement tocontainsinformation on improvingoutcomes in diabetes throughthe appropriate use of newtechnologies and innovativebenefit design strategies.
Faculty
Andrew J. Ahmann, MD, MS
Associate Professor of Medicine
Division of Endocrinology, Diabetes and Clinical Nutrition
Oregon Health and Science University
Director, Diabetes Care Center
Portland, Oregon
Jan Berger, MD, MJ
Senior Vice President
Chief Clinical Officer
Caremark Inc
North Brook, Illinois
Lawrence Blonde, MD, FACP, FACE
Director
Ochsner Diabetes Clinical Research Unit
Section on Endocrinology, Diabetes, and Metabolism
Associate Residency Program Director
Department of Internal Medicine
Ochsner Clinic Foundation
New Orleans, Louisiana
Curtis L.Triplitt, PharmD, CDE
Assistant Professor
Department of Medicine
Division of Diabetes
Clinical Assistant Professor of Pharmacy
Clinical Pharmacy Program
University of Texas Health Science Center
San Antonio, Texas
Faculty Disclosures
These participants report relationships with the following pharmaceuticalcompanies:
Andrew J. Ahmann, MD, MS
Consultant:
- The Amylin-Lilly Alliance
- Ortho-Clinical Diagnostic
- sanofi-aventis
Speaker's Bureau:
- The Amylin-Lilly Alliance
- Novo Nordisk
- sanofi-aventis
Jan Berger, MD, MJ
Stockholder/Employee:
- Caremark
Lawrence Blonde, MD, FACP, FACE
Research Funding:
- Amylin
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- MannKind Corporation
- Merck
- Novartis
- Novo Nordisk
- Pfizer
- sanofi-aventis
Consultant and Speaker:
- Abbott
- Amylin
- Eli Lilly
- GlaxoSmithKline
- Lifescan
- Merck/Schering-Plough
- Novartis
- Pfizer
- sanofi-aventis
Speaker:
- Takeda
- Wyeth
Consultant:
- AstraZeneca
Curtis L.Triplitt, PharmD, CDE
Speaker:
- Novartis Pharmaceuticals
- Pfizer Inc
- sanofi-aventis
Advisory Board:
- Amylin
The American Journal of
Managed Care
Signed disclosures are on file at the office of , Princeton, New Jersey.
The American
Journal of Managed Care
It is the policy of to haveall faculty who participate inprograms sponsored bypharmaceutical companiesdisclose any real or apparentconflicts of interest.
It is the policy of BCMEto require the disclosure ofany financial relationships orother relationships that afaculty member has with themanufacturers of any commercialproducts or providers relevantto the topics or therapeutic areasbeing discussed.
STAFF DISCLOSURES
BCME staff members andreviewers involved in clinicalcontent development have norelevant financial relationshipsto disclose.
BCME has received educationalgrants from The Amylin-LillyAlliance for CE/CME activities.
This CME activity was planned and produced in accordance with the Accreditation Council for Continuing MedicalEducation Essential Areas and Policies.
ACTIVITY OVERVIEW
This activity will update participants on the state of diabetes in the United States, including epidemiology, consensusguidelines, and performance measures designed to evaluate and improve management of this population. This activitywill ensure that managed care professionals are informed about new and investigational pharmacotherapeutic agents andtechnologies in the diabetes armamentarium. New benefit design strategies and their potential application to this diseasestate will be discussed, explored, and debated.
TARGET AUDIENCE
This activity is for managed healthcare professionals, especially pharmacy directors and medical directors, with an interestin improving members'outcomes in diabetes through the appropriate use of new technologies and innovative benefitdesign strategies.
EDUCATIONAL OBJECTIVES
After completing this educational supplement, the participant should be able to:
- Describe some of the current gaps in the management of diabetes in the US healthcare system.
- Recognize current standards of care for the management of diabetes and available quality improvementinitiatives to help optimize health outcomes.
- Evaluate new and emerging diabetes technologies and classes of medications to determine theirappropriate place in therapy.
- Analyze the potential impact of novel pharmacy benefit designs in diabetes management.
ACCREDITATION AND CREDIT DESIGNATION
The Bimark Center for Medical Education (BCME) is accredited by the Accreditation Council for PharmacyEducation (ACPE) as a provider of continuing pharmacy education (No. 799).
This program is acceptable for 2.0 hours (0.2 CEU) of continuing education credit in states that recognize ACPE-accreditedproviders. The ACPE Universal Program Number for this program is 799-000-07-002-H01.
The BCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical education for physicians.
AMA PRA Category 1 Credits
BCME designates this educational activity for a maximum of 2 ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
COMMERCIAL SUPPORT
This activity is supported by an educational grant from Amylin Pharmaceuticals and Eli Lilly and Company.
Initial Release Date: April 1, 2007
Expiration Date: April 1, 2008
DISCLOSURE OF UNLABELED/UNAPPROVED USES OF DRUGS OR DEVICES
Participants are advised that some of the discussions in this continuing medical education activity may contain referencesto unlabeled or unapproved uses of drugs or devices, and are indicated as such throughout the activity.
•••
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
Articles in this issue
over 18 years ago
CME/CE Questionsover 18 years ago
New Technologies and Therapies in the Management of Diabetesover 18 years ago
State of Diabetes Care in the United Statesover 18 years ago
Guidelines and Performance Measures for DiabetesNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.